A selection of short essays from our blog, written to empower our clients with modeling and simulation (M&S), regulatory science, and real-world value assessment solutions to help them solve the toughest drug development problems. In the Best of the Blog, Certara’s scientists and regulatory experts share their learnings, technological advances, and thought leadership.
“Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled” Bob Dylan recorded his iconic “The Times They Are a Changin’” in 1963; the song was released on the 1964 album by the same name. One of […]
High prices for drugs for rare diseases have introduced uncertainties from payers around whether a medication’s value justifies its price.
Model-based meta-analysis is a quantitative framework that uses PK/PD and statistical modeling of external data to inform drug development decisions.
The Certara Quantitative Systems Toxicology & Safety (QSTS) Pharma Consortium: Overview and Invitation to Join
Quantitative Systems Toxicology Approach Integrates Simcyp PBPK and Core Hepatocyte Metabolism: a Case Study with Valproic Acid
Organ-on-chip systems aim to recapitulate human physiology in vitro and hold the promise to revolutionize drug development.